These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 34816789

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA.
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [Abstract] [Full Text] [Related]

  • 3. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.
    J Clin Oncol; 2017 Jul 10; 35(20):2299-2305. PubMed ID: 28410011
    [Abstract] [Full Text] [Related]

  • 4. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley WU, Pandharipande PV, Efstathiou JA.
    Clin Genitourin Cancer; 2019 Feb 10; 17(1):23-31.e3. PubMed ID: 30482661
    [Abstract] [Full Text] [Related]

  • 5. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G, Strigari L, Arcangeli S.
    Crit Rev Oncol Hematol; 2015 Sep 10; 95(3):387-96. PubMed ID: 25934521
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL.
    J Clin Oncol; 2014 Dec 01; 32(34):3801-9. PubMed ID: 25366678
    [Abstract] [Full Text] [Related]

  • 7. [The effect of tri-modality therapy on the treatment of muscle-invasive bladder cancer].
    Wang JF, Zhou XF, Fang DB, Wu ZM, Ding ZS, Chen X, Liu NB.
    Zhonghua Yi Xue Za Zhi; 2018 May 29; 98(20):1614-1616. PubMed ID: 29886656
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
    Seisen T, Sun M, Lipsitz SR, Abdollah F, Leow JJ, Menon M, Preston MA, Harshman LC, Kibel AS, Nguyen PL, Bellmunt J, Choueiri TK, Trinh QD.
    Eur Urol; 2017 Oct 29; 72(4):483-487. PubMed ID: 28412065
    [Abstract] [Full Text] [Related]

  • 11. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
    Ecke TH, Stier K, Weickmann S, Zhao Z, Buckendahl L, Stephan C, Kilic E, Jung K.
    Cancer Med; 2017 Oct 29; 6(10):2252-2262. PubMed ID: 28879675
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kübler H, Stenzl A, Gakis G.
    Urol Oncol; 2018 Feb 29; 36(2):43-53. PubMed ID: 29102254
    [Abstract] [Full Text] [Related]

  • 14. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
    Koie T, Ohyama C, Yamamoto H, Hatakeyama S, Imai A, Yoneyama T, Hashimoto Y, Kitayam M, Hirota K.
    Urol Oncol; 2014 Aug 29; 32(6):820-5. PubMed ID: 24951323
    [Abstract] [Full Text] [Related]

  • 15. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).
    Arcangeli G, Arcangeli S, Strigari L.
    Crit Rev Oncol Hematol; 2015 Apr 29; 94(1):105-15. PubMed ID: 25541350
    [Abstract] [Full Text] [Related]

  • 16. Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study.
    Ballas LK, Navarro S, Luo C, Fossum CC, Farias A, Daneshmand S, Groshen S.
    Cancer Med; 2021 May 29; 10(9):3004-3012. PubMed ID: 33779053
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.
    Zhang J, Zhou X, Ding H, Wang L, Liu S, Liu Y, Chen Z.
    BMC Urol; 2020 Mar 19; 20(1):31. PubMed ID: 32192483
    [Abstract] [Full Text] [Related]

  • 20. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
    Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, Kelly JD, Kirkbank T, McLaren DB, Mead G, Moynihan C, Persad R, Scrase C, Lewis R, Hall E.
    BJU Int; 2017 Nov 19; 120(5):639-650. PubMed ID: 28453896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.